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Original Article

Comparison of perioperative outcomes among non-small cell lung
cancer patients with neoadjuvant immune checkpoint inhibitor
plus chemotherapy, EGFR-TKI, and chemotherapy alone: a realworld evidence study
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Background: The utilization of neoadjuvant immune checkpoint inhibitor (ICI) plus chemotherapy has
increased significantly for resectable non-small cell lung cancer (NSCLC). It is still unclear whether such a
treatment paradigm affects perioperative outcomes compared with other neoadjuvant treatment. We aimed
to evaluate the perioperative outcomes of pulmonary resection after neoadjuvant ICI plus chemotherapy and
to compare them with neoadjuvant epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI)
and neoadjuvant chemotherapy alone for resectable NSCLC.
Methods: A retrospective cohort including 194 stage IB–IIIB NSCLC underwent surgical resection after
neoadjuvant treatment between 2018 and 2020 were reviewed. Perioperative complications were evaluated
using the Common Terminology Criteria for Adverse Events, and were compared using one-way analysis of
variance for continuous variables and Pearson chi-square test.
Results: There were 42, 54, and 98 patients in the neoadjuvant ICI plus chemotherapy, EGFR-TKI, and
chemotherapy alone groups, respectively. The tumor size before neoadjuvant treatment was well balanced
among the three groups (P=0.122). A shorter median surgical time was observed in the EGFR-TKI group
than ICI plus chemotherapy group and chemotherapy group alone (120 vs. 150 vs. 146 min, P=0.041). Videoassisted thoracoscopic surgery was performed in 37 (88.1%), 49 (90.7%), and 57 (58.7%) patients in the three
groups, respectively (P<0.001). A higher incidence of pneumonia (P=0.014) was found in the chemotherapy
group. Perioperative mortality was observed in 1 patient (2.4%) in the ICI plus chemotherapy group and
in 3 patients (3.1%) in the chemotherapy alone group (P=0.440). Patients in the ICI plus chemotherapy
group had higher proportions of pathological complete response (40.5% vs. 11.1% vs. 6.1%, P<0.001) and
downstaging of clinical N2 status (68.6% vs. 42.9% vs. 31.7%, P=0.012) than patients in EGFR-TKI group
and chemotherapy alone group.
Conclusions: Surgical resection for NSCLC following neoadjuvant ICI plus chemotherapy was safe and
feasible, the perioperative outcomes were similar with neoadjuvant EGFR-TKI and chemotherapy alone without
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unexpected perioperative complications. Additional prospective studies are necessary to validate our findings.
Keywords: Non-small cell lung cancer (NSCLC); neoadjuvant; immune checkpoint inhibitor (ICI); perioperative
outcomes
Submitted Mar 22, 2022. Accepted for publication Jul 15, 2022.
doi: 10.21037/tlcr-22-476
View this article at: https://dx.doi.org/10.21037/tlcr-22-476

Introduction
Surgical resection remains the most effective treatment
strategy for potentially resectable non-small cell lung cancer
(NSCLC). The 5-year overall survival rates among surgically
resected NSCLC range from 83% for stage IA disease to
26% for stage IIIB disease, with most mortality patients
undergoing postoperative relapse (1). Utilizing neoadjuvant
chemotherapy is one approach that attempts to augment
the outcomes afforded by surgery alone. A limitation of this
strategy, however, is that the actual proportion of patients
achieving a pathological complete response (pCR) is low,
and there is a considerable incidence of toxicity (2,3).
Immune checkpoint inhibitors (ICIs) that block the
programmed death-1 (PD-1) pathway have revolutionized
the cancer treatment landscape (4-6). The monotherapy
of nivolumab accomplished a pCR in 15% resected tumor.
Interestingly, the combination of ICI with chemotherapy
has shown a significant survival advantage in metastatic
NSCLC, generating considerable enthusiasm for the use of
ICI plus chemotherapy when treating early-stage resectable
NSCLC (7). Incorporating ICI and chemotherapy into the
management of early-stage NSCLC is attractive because
the primary tumor may release neoantigens from dying
tumor cells and activate tumor-specific T cells before
surgical resection (8,9). Previous clinical trials have found
that neoadjuvant ICI plus chemotherapy were associated
with a higher proportion of patients achieving pCR (10,11).
Recently, the CheckMate 816 study, the first of several phase
III trials evaluating neoadjuvant ICI plus chemotherapy,
resulted in a significantly longer median event-free survival
(31.6 vs. 20.8 months) and higher percentage of pCR
(24.0% vs. 2.2%) than chemotherapy alone in resectable
NSCLC (12). Furthermore, the treatment-related adverse
events of neoadjuvant ICI were observed to be acceptable
and not associated with surgery delays.
In contrast to traditional platinum-based neoadjuvant
chemotherapy, ICI that regulate the immune-inhibitory
pathway of patients to release their own anti-tumor
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immunity has attracted special attention on the perioperative
outcomes. The unique mechanism of neoadjuvant ICI
plus chemotherapy may increase the risk of pneumonitis
and adhesion, which can, theoretically, lead to technical
challenges for lung resections (13). However, reports
regarding the surgical technique and the perioperative
outcomes of surgical resection after neoadjuvant ICI
plus chemotherapy in NSCLC, especially in comparison
with traditional neoadjuvant chemotherapy, are scarce.
Moreover, epidermal growth factor receptor (EGFR)
mutation is present in 39% to 59% NSCLC patients in
East Asia population, which are predictive of response to
EGFR-tyrosine kinase inhibitors (TKI) (14-17). Zhong
et al. reported that patients with neoadjuvant EGFR-TKI
have significantly longer progression-free survival versus
neoadjuvant chemotherapy (18).
Therefore, the objective of this study was to evaluate
the perioperative complications and mortalities of surgical
resection after neoadjuvant ICI plus chemotherapy and
comprehensively compare these outcomes with neoadjuvant
EGFR-TKI and neoadjuvant chemotherapy alone in
patients with resectable NSCLC. We present the following
article in accordance with the STROBE reporting
checklist (available at https://tlcr.amegroups.com/article/
view/10.21037/tlcr-22-476/rc).
Methods
Ethical statement
This is a retrospective, sing-center study. We retrospectively
enrolled patients who underwent neoadjuvant ICI plus
chemotherapy, neoadjuvant EGFR-TKI, and neoadjuvant
chemotherapy alone from Shanghai Pulmonary Hospital.
The study was conducted in accordance with the Declaration
of Helsinki (as revised in 2013). This study was approved
by the Institutional Review Board of Shanghai Pulmonary
Hospital (No. L21-224), and written informed consent was
waived due to the retrospective nature of the study.
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Study population and procedures

performed approximately 4 weeks after the 1st day of the last
treatment cycle. When patients were unable to tolerate the
treatment-related adverse effects, or there was local disease
progression according to the Response Evaluation Criteria
in Solid Tumors (RECIST, version 1.1), the patients were
taken immediately to surgery. A repeat chest CT scan and
pulmonary function test were required within 7 days before
surgery. Resection of the primary tumor and systematic
mediastinal lymph node (LN) dissection were performed.
Postoperative ICI plus chemotherapy or chemotherapy
alone was administered within 3 to 8 weeks after complete
resection were administered. The pathological response
was assessed using routine hematoxylin and eosin staining
by measuring the percentage of residual viable tumor in the
resected primary tumor. Major pathologic response (MPR)
was defined as no more than 10% viable tumor cells in the
resected primary tumor (19).

A total of 42 patients with NSCLC who received
neoadjuvant ICI plus chemotherapy between January
2018 and December 2020 were reviewed. Patients with
history of previous cancer, positive tumor driver mutation,
and ICI-only neoadjuvant therapy were excluded. All
enrolled patients were diagnosed with clinical stage IB
to IIIB disease according to the 8th edition of the tumor,
node, metastasis (TNM) classification for lung cancer.
To compare the perioperative outcomes of neoadjuvant
ICI plus chemotherapy with neoadjuvant EGFR-TKI
and neoadjuvant chemotherapy, 54 patients who received
neoadjuvant EGFR-TKI and 98 patients who received
neoadjuvant chemotherapy during the same period also
were evaluated.
All patients underwent a standard staging workup
before treatment, including a chest computed tomography
(CT) scan, abdominal CT scan, and magnetic resonance
imaging of the brain. Positron emission tomography (PET)/
CT scan and endobronchial ultrasound (EBUS)-guided
transbronchial needle aspirations were also performed
when necessary. Patients with central tumor and hilar or
mediastinal lymphadenopathy on CT scan were required
to undergo a PET-CT scan or EBUS examination for
precise staging before neoadjuvant treatment. In addition,
a tumor biopsy was mandatory for histological diagnosis
and mutation detection before neoadjuvant treatment.
The strategy of neoadjuvant treatment was decided upon
patients’ profile, driver mutation status, and discussion by
a group of oncologists, surgeons, and radiologists together.
Patients in the chemotherapy alone group received 2–4
of cycles of platinum-based doublet chemotherapy before
surgery. Additionally, the same regimens of adjuvant
chemotherapy for two cycles were performed after complete
resection or until disease progression or unacceptable
toxicity. For patients harboring EGFR mutations (EGFRTKI group), standard doses of EGFR-TKIs, such as
gefitinib, icotinib, erlotinib, and afatinib, were administered
daily during 3 to 6 weeks before surgery. Postoperative
adjuvant treatment using either EGFR-TKI or platinumbased chemotherapy was chosen on the basis of the patient’s
condition and the clinical experience of the medical
oncologist.
Eligible patients in the neoadjuvant ICI group received
pembrolizumab (200 mg) and platinum-based doublet
chemotherapy on day 1 of each 21-day cycle, with a total of
2–4 cycles before surgical resection. Generally, surgery was
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Surgical techniques
Video-assisted thoracoscopic surgery (VATS) was the
preferred surgical approach at our center. Detailed surgical
procedures for VATS lobectomy and pneumonectomy
have been described in our previous studies (20,21).
Sleeve lobectomy generally was performed at our center
for centrally located tumors to avoid pneumonectomy
(22,23). For uniportal VATS sleeve lobectomy, a 3–5 cm
incision at the 4th intercostal space of the anterior axillary
line was drawn. An intraoperative frozen section was
required to confirm that the tumor was free of proximal
and distal margins. A systematic hilar and mediastinal LN
dissection was performed before the anastomosis. The
inferior pulmonary ligament was always released to reduce
anastomotic tension. Subsequently, end-to-end bronchial
anastomosis was performed using continuous sutures with a
3-0 Prolene running suture (Video 1).
Variables studied and statistical analysis
The demographic information, clinical and pathologic
characteristics, data about neoadjuvant therapy, surgical
outcomes, and perioperative complications were collected
from the medical record system. All clinical and pathological
classifications were recorded in accordance with the 8 th
edition of the TNM staging system (1). A peripheral tumor
was defined as a tumor located in the outer 3rd of the lung on
the CT scan. The Charlson Comorbidity Index (CCI) was
used to describe comorbidities (24). Perioperative mortality
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Video 1 Uniportal VATS sleeve lobectomy for left upper lobe.
VATS, video-assisted thoracoscopic surgery.

was defined as death from any cause within 30 days after
surgery. Prolonged air leakage was defined as lasting for
more than 7 days after surgery. Postoperative complications
were evaluated using the Common Terminology Criteria
for Adverse Events (version 5.0).
Continuous variables are presented as the mean ±
standard deviation or the median value with the interquartile
range (IQR). Categorical variables are presented as
frequency and percentage. Baseline characteristics and
perioperative outcomes were compared among the
ICI plus chemotherapy group, EGFR-TKI group, and
chemotherapy alone group using 1-way analysis of variance
for continuous variables and Pearson chi-square test or
Fisher exact test for categorical variables. A 2-sided P value
of less than 0.05 was considered statistically significant. All
statistical analyses were performed using SPSS 26.0 (IBM
Corporation, Armonk, NY, USA).
Results
Baseline characteristics
Between January 2018 and December 2020, 42 patients
received neoadjuvant ICI plus chemotherapy followed by
surgical resection. During the same period, 54 patients
received neoadjuvant EGFR-TKI and 98 patients received
neoadjuvant chemotherapy alone followed by surgical
resection. The baseline characteristics of these three groups
are listed and compared in Table 1.
Patients in the ICI plus chemotherapy group and
chemotherapy alone group had higher proportions of male
patients (95.2% vs. 84.7% vs. 44.4%, P<0.001), higher
proportions of smoking history (57.1% vs. 46.9% vs. 18.5%,
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P<0.001), more centrally located tumors (54.8% vs. 44.9%
vs. 16.7%, P<0.001), and more advanced clinical TNM
stages (stage II to III, 97.6% vs. 94.9% vs. 87.0%, P=0.003)
compared with patients in the EGFR-TKI group. In addition,
patients in the ICI plus chemotherapy and chemotherapy
alone groups had and compared with patients in the EGFRTKI group. Patients in the ICI plus chemotherapy group and
EGFR-TKI group had similar radiologic tumor size with
chemotherapy alone group before neoadjuvant treatment
(4.7 vs. 3.9 vs. 4.2 cm, P=0.122), but significantly smaller
tumor size after neoadjuvant treatment (3.5 vs. 2.6 vs. 2.6 cm,
P=0.005). According to RESCIST version 1.1 criteria, 25
(59.5%), 23 (42.6%), and 22 (22.4%) patients achieved
radiological response (P=0.001) in the ICI, EGFR-TKI, and
chemotherapy groups, respectively. Representative radiologic
images of the lesion before and after the neoadjuvant
ICI plus chemotherapy treatment are shown in Figure 1.
There were no significant differences among the three
groups in terms of age, forced expiratory volume in 1 second
of predicted value, body mass index, and CCI.
Perioperative outcomes
All patients underwent R0 resection and no intraoperative
deaths were observed. Table 2 shows the perioperative
outcomes of the three groups. The median interval times
from last treatment to surgery were 36 (IQR, 31–41), 12
(IQR, 5–21), and 37 (IQR, 30–49) days for the ICI, EGFRTKI, and chemotherapy groups (P<0.001), respectively. No
treatment-related surgical delay was observed. Patients in
the ICI plus chemotherapy group and chemotherapy alone
group were associated with higher proportions of sleeve
lobectomies compared with those in the EGFR-TKI group
(33.3% vs. 21.4% vs. 11.1%, P=0.001). There were 37 cases
(88.1%), 49 cases (90.7%), and 57 cases (58.2%) resected via
VATS approach in the ICI, EGFR-TKI, and chemotherapy
groups, respectively (P<0.001).
Patients in the ICI plus chemotherapy group and
chemotherapy alone group had longer operative time
than those in the EGFR-TKI group (150 vs. 146 vs.
120 minutes, P=0.041). The number of examined LNs,
estimated blood loss, rates of postoperative transfusion,
and postoperative hospital stay were evenly distributed
among the three groups. The perioperative mortality within
30 days was 2.4%, 0%, and 3.1% for the ICI, EGFRTKI, and chemotherapy groups, respectively (P=0.440).
One patient in the ICI plus chemotherapy group died due
to bronchopleural fistula after sleeve lobectomy. Three
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Table 1 Comparison of baseline characteristics among the three groups
Variables

ICI plus chemotherapy (N=42) EGFR-TKI (N=54)

Age (years), mean ± SD

61.3±9.1

59.3±9.2

Chemotherapy alone (N=98)

P value

60.7±7.3

0.470

Gender, n (%)
Male
Female

<0.001
40 (95.2)

24 (44.4)

83 (84.7)

2 (4.8)

30 (55.6)

15 (15.3)

Smoking history, n (%)
Never

<0.001
18 (42.9)

44 (81.5)

52 (53.1)

24 (57.1)

10 (18.5)

46 (46.9)

BMI (kg/m ), mean ± SD

25.2±3.0

24.6±3.5

23.6±3.0

0.043

FEV1% (of predicted), mean ± SD

89.1±23.6

91.1±15.2

88.8±17.2

0.742

PET-CT

34 (81.0)

29 (53.7)

42 (42.9)

<0.001

EBUS

24 (57.1)

21 (38.9)

52 (53.1)

0.143

Current/former
2

Preoperative staging, n (%)

Tumor location, n (%)

0.241

Upper lobe

26 (61.9)

33 (61.1)

60 (61.2)

Middle lobe

2 (4.8)

7 (13.0)

4 (4.1)

Lower lobe

14 (33.3)

14 (25.9)

34 (34.7)

Central/peripheral lesion, n (%)

<0.001

Central

23 (54.8)

9 (16.7)

44 (44.9)

Peripheral

19 (45.2)

45 (83.3)

54 (55.1)

Before neoadjuvant treatment

4.7±2.1

3.9±1.5

4.2±1.8

0.122

After neoadjuvant treatment

2.6±1.3

2.6±1.0

3.5±1.8

0.005

Radiologic tumor size (cm), mean ± SD

Clinical TNM stage, n (%)

0.003

I

1 (2.4)

7 (13.0)

5 (5.1)

II

1 (2.4)

2 (3.7)

18 (18.4)

III

40 (95.2)

45 (83.3)

75 (76.5)

Radiologic response (RESCIST 1.1 criteria), n (%)

0.001

Partial response

25 (59.5)

23 (42.6)

22 (22.4)

Stable disease

9 (21.4)

21 (38.9)

48 (49.0)

0 (0)

3 (5.6)

8 (8.2)

8 (19.0)

7 (13.0)

20 (20.4)

Progressive disease
Unavailable
Histology, n (%)

<0.001

Adenocarcinoma

8 (19.0)

53 (98.1)

37 (37.8)

Squamous cell carcinoma

29 (69.0)

0 (0)

53 (54.1)

Other/unspecific

5 (11.9)

1 (1.9)

8 (8.2)

Table 1 (continued)
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Table 1 (continued)
Variables

ICI plus chemotherapy (N=42) EGFR-TKI (N=54)

Chemotherapy alone (N=98)

Charlson Comorbidity Index, n (%)

P value
0.568

0

5 (11.9)

9 (16.7)

9 (9.2)

1

9 (21.4)

13 (24.1)

14 (14.3)

2

19 (45.2)

22 (40.7)

46 (46.9)

3

5 (11.9)

8 (14.8)

18 (18.4)

4

4 (9.5)

2 (3.7)

11 (11.2)

ICI, immune checkpoint inhibitor; EGFR-TKI, epidermal growth factor receptor tyrosine kinase inhibitors; SD, standard deviation; BMI,
body mass index; FEV1, forced expiratory volume in one second; PET-CT, positron emission tomography-computed tomography; EBUS,
endobronchial ultrasound; TNM, tumor, node, metastasis.

B

Patient 1

A

Before ICI plus chemotherapy

D

Patient 2

C

After ICI plus chemotherapy

Before ICI plus chemotherapy

F

Patient 3

E

After ICI plus chemotherapy

Before ICI plus chemotherapy

After ICI plus chemotherapy

Figure 1 Representative radiologic changes before neoadjuvant ICI plus chemotherapy and before surgery. (A,B) Radiologic imaging
before and after neoadjuvant ICI plus chemotherapy of patient 1, who finally underwent lobectomy; (C,D) radiologic imaging before and
after neoadjuvant ICI plus chemotherapy of patient 2, who finally underwent sleeve lobectomy; (E,F) radiologic imaging before and after
neoadjuvant ICI plus chemotherapy of patient 3, who finally underwent pneumonectomy. The arrows indicate tumor lesion. ICI, immune
checkpoint inhibitor.
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Table 2 Comparisons of surgical outcomes
Perioperative outcomes
Time from last treatment to surgery (days),
median [IQR]

ICI plus chemotherapy (N=42) EGFR-TKI (N=54) Chemotherapy alone (N=98)
36 [31–41]

12 [5–21]

37 [30–49]

Extent of resection, n (%)

<0.001
0.001

Lobectomy

19 (45.2)

45 (83.3)

49 (50.0)

Bilobectomy

6 (14.3)

1 (1.9)

19 (19.4)

Sleeve lobectomy

14 (33.3)

6 (11.1)

21 (21.4)

Pneumonectomy

3 (7.1)

2 (3.7)

9 (9.2)

Surgical approach, n (%)
VATS

P value

<0.001
37 (88.1)

49 (90.7)

57 (58.2)

Thoracotomy

4 (9.5)

4 (7.4)

36 (36.7)

VATS convert to thoracotomy

1 (2.4)

1 (1.9)

5 (5.1)

15.3±8.4

14.1±7.4

16.2±7.9

0.271

Examined N1 nodes

7.7±4.5

6.4±4.2

7.3±4.0

0.249

Examined N2 nodes

9.6±5.3

8.3±4.2

9.4±5.3

0.335

150 [120–180]

120 [99–167]

146 [120–180]

0.041

50 [50–100]

50 [50–100]

100 [50–150]

0.846

Required for postoperative transfusion, n (%)

5 (11.9)

8 (14.8)

6 (6.1)

0.197

Postoperative stay (days), median [IQR]

5 [4–7]

3 [3–6]

5 [4–7]

0.164

Perioperative mortality, n (%)

1 (2.4)

0 (0)

3 (3.1)

0.440

Any complications

7 (16.7)

3 (5.6)

24 (24.5)

0.013

Bronchopleural fistula

2 (4.8)

0 (0)

1 (1.0)

0.144

Hemothorax

0 (0)

0 (0)

2 (2.0)

0.372

Chylothorax

0 (0)

0 (0)

2 (2.0)

0.372

Prolonged air leak

2 (4.8)

1 (1.9)

3 (3.1)

0.714

Pneumonia

3 (7.1)

1 (1.9)

16 (16.3)

0.014

0 (0)

1 (1.9)

0 (0)

0.272

Total number of examined LNs, mean ± SD

Surgical time (min), median [IQR]
Estimated blood loss (mL), median [IQR]

Postoperative complications, n (%)

Pulmonary embolism

ICI, immune checkpoint inhibitor; EGFR-TKI, epidermal growth factor receptor tyrosine kinase inhibitors; IQR, interquartile range; VATS,
video-assisted thoracoscopic surgery; LN, lymph node; SD, standard deviation.

patients in the chemotherapy alone group died due to
chylothorax, food aspiration, and hemothorax, respectively.
The overall postoperative complications were
significantly higher in the ICI plus chemotherapy group
and chemotherapy alone group than the EGFR-TKI group
(16.7% vs. 24.5% vs. 5.6%, P=0.013). Patients in the ICI
plus chemotherapy group and EGFR-TKI group were
associated with a significantly lower rate of pneumonia than

© Translational Lung Cancer Research. All rights reserved.

patients in the chemotherapy alone group (7.1% vs. 1.9%
vs. 16.3%, P=0.014). Hemothorax, chylothorax, prolonged
air leak, and pulmonary embolism were similar among
the three groups. Bronchopleural fistula occurred more
frequently in the ICI plus chemotherapy group than the
EGFR-TKI and chemotherapy alone groups (4.8% vs. 0%
vs. 1.0%), but the difference was not statistically significant
(P=0.144).
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Table 3 Tumor response according to different neoadjuvant treatment strategy
Variables

ICI plus chemotherapy (N=42)

EGFR-TKI (N=54) Chemotherapy alone (N=98)

Pathologic response, n (%)

<0.001

Pathologic complete response

17 (40.5)

6 (11.1)

6 (6.1)

Major pathologic response

30 (71.4)

11 (20.4)

14 (14.3)

<90% response

12 (28.6)

43 (79.6)

84 (85.7)

yp TNM stage, n (%)

0.002

I

29 (69.0)

27 (50.0)

33 (33.7)

II

3 (7.1)

6 (11.1)

23 (23.5)

III

10 (23.8)

21 (39.9)

42 (42.8)

2.9±1.7

2.6±1.0

3.4±1.7

Pathological tumor size (cm), mean ± SD

P value

Downstaging of nodal status for N2 disease , n (%)

0.018
0.012

N2 to pN0

24 (68.6)

15 (42.9)

19 (31.7)

N2 to pN1

1 (2.8)

4 (11.4)

9 (15.0)

N2 to pN2

10 (28.6)

16 (45.7)

32 (53.3)

ICI, immune checkpoint inhibitor; EGFR-TKI, epidermal growth factor receptor tyrosine kinase inhibitors; TNM, tumor, node, metastasis;
SD, standard deviation.

Tumor response to neoadjuvant treatment
A higher proportion of patients in the ICI plus
chemotherapy group achieved pCR (17/42, 40.5%) and
MPR (30/42, 71.4%) compared with patients in the EGFRTKI group (pCR: 6/54, 11.1%; MPR: 11/54, 20.4%)
and chemotherapy alone group (pCR: 6/98, 6.1%; MPR:
14/98, 14.3%) (Table 3). Furthermore, the proportion of
downstaging of nodal status from clinical N2 disease to
pathologic N0 disease was significantly higher in the ICI
group (68.6%, 42.9%, and 31.7% for the ICI, EGFR-TKI,
and chemotherapy groups, respectively, P=0.012).
Discussion
Incorporating ICI plus chemotherapy into the management
of early-stage resected NSCLC is now an area of active
investigation (7,10,11). However, concerns about the
feasibility and safety of surgical resection after neoadjuvant
ICI still exist as mediastinal or hilar inflammation/fibrosis
might develop in response to treatment. In this study, we
reviewed 42 patients who received neoadjuvant ICI plus
chemotherapy followed by surgical resection and found
that neoadjuvant ICI was associated with a higher rate of
achieving MPR and a similar postoperative mortality and
morbidity compared with neoadjuvant EGFR-TKI and
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neoadjuvant chemotherapy alone in resectable NSCLC.
To the best of our knowledge, this is the first study to
comprehensively evaluate perioperative outcomes after
neoadjuvant ICI plus chemotherapy and compare it to other
neoadjuvant regimens.
Neoadjuvant ICI in resected NSCLC was first reported
in 2018. Two doses of nivolumab were associated with 45%
of cases achieving MPR and 10% of cases achieving pCR (7).
Recent phase II trials also have shown that 57–74% of
patients experience MPR after neoadjuvant ICI, and
without treatment-related surgical delays (10,11). In this
study, the proportion of patients achieving MPR was 71.4%
in the neoadjuvant ICI plus chemotherapy group, which was
significantly higher than in the neoadjuvant EGFR-TKI and
neoadjuvant chemotherapy alone groups, and no treatmentrelated surgical delay was observed. The effectiveness
and safety of neoadjuvant ICI plus chemotherapy have
been corroborated by the CheckMate 816 study (12).
The perioperative outcomes after neoadjuvant ICI plus
chemotherapy have not been evaluated comprehensively
and compared with standard neoadjuvant chemotherapy
alone, despite the emergence of numerous clinical trials
using neoadjuvant ICI (25).
Yang et al. first evaluated surgical outcomes after
neoadjuvant ipilimumab plus chemotherapy for stage II-IIIA
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NSCLC based on a phase II trial (TOP1201), demonstrating
the safety and feasibility of surgical resection (26). Bott
et al. reported perioperative outcomes after neoadjuvant
nivolumab based on a randomized trial and concluded
that the surgery, while challenging, could be accomplished
safely (13). Minimally invasive resections have been
shown to be performed safely following monotherapy
of ICI. However, more than half of VATS or robotic
cases were converted to thoracotomy often because of
hilar inflammation and fibrosis. In the current study, all
patients were completely resected and most of the tumors
(88.1%) were resected via VATS after neoadjuvant ICI plus
chemotherapy, which is higher than previous reports (26,27).
There was only one patient in the ICI plus chemotherapy
group converted to thoracotomy due to severe hilar fibrosis.
It is worth noting that patients in the chemotherapy alone
group had a larger tumor size before surgery, which can
explain a lower use of VATS resections and thereby a
higher proportion of postoperative pneumonia associated
with thoracotomies. Ultimately, this study showed that
neoadjuvant ICI plus chemotherapy was not associated
with unexpected perioperative mortality or postoperative
complications compared with neoadjuvant EGFR-TKI and
neoadjuvant chemotherapy alone.
Thomas et al. reported that neoadjuvant chemotherapy
increased treatment-related mortality compared to
patients without neoadjuvant chemotherapy, especially
in patients undergoing a pneumonectomy (14% vs. 6%),
which led to the absence of a progression-free survival
benefit (28). In this study, 7.3% of patients underwent
pneumonectomy after neoadjuvant treatment, and the
associated perioperative mortality was 7.1%. One patient
in the chemotherapy group experienced food aspiration,
leading to severe pneumonia and ongoing hypoxemia and
eventually, death. In this study, neoadjuvant treatment was
not associated with a higher rate of perioperative mortality
after pneumonectomy compared with those without
neoadjuvant treatment, which is consistent with the findings
of a previous study (29).
Sleeve lobectomy is an optional surgical procedure
to improve postoperative quality of life compared with
pneumonectomy for centrally located NSCLC, but it
remains challenging, especially via VATS (30). Yang et al.
reported that sleeve lobectomy achieved superior
perioperative outcomes and equivalent oncological
efficacies compared with pneumonectomy (31). In this
study, 76 patients with centrally located NSCLC received
neoadjuvant treatment, and 41 patients eventually

were resected by sleeve lobectomy. Additionally, sleeve
lobectomy was associated with a shorter hospital stay
and similar postoperative complications compared with
pneumonectomy (Table S1). Our previous study also found
double sleeve lobectomy after neoadjuvant chemotherapy
is safe and no perioperative mortality in patients with
centrally-located NSCLC than those without neoadjuvant
chemotherapy (32). In the current study, one (7.1%) sleeve
lobectomy patient in the ICI plus chemotherapy group
experienced bronchopleural fistula and eventually die. We
believe that the safety of sleeve lobectomy after ICI plus
chemotherapy need more evidence to verify.
This study had several limitations. First, the smaller
sample size for the neoadjuvant ICI patients may have
limited the statistical power, and the effect of the surgical
extent and surgical approach on perioperative outcomes
were not available. Second, the results were derived from
retrospective study, using a single-center database, with
inevitable selection bias. Some clinicopathologic factors,
such as gender, smoking history, histologic subtype, and
treatment cycles may not be well balanced. Prospective
multicenter clinical trials are required to provide more
evidence. Third, the baseline characteristics among the
three groups were imbalanced. The results of additional
forthcoming prospective studies on this topic should address
this issue.
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Conclusions
Surgical resection after neoadjuvant ICI plus chemotherapy
appeared to be safe and feasible without unexpected
perioperative complications and mortalities for patients
with resected NSCLC compared with neoadjuvant
EGFR-TKI and neoadjuvant chemotherapy alone, and
our experience suggested that most of these procedures
could be accomplished with VATS approach. Additional
prospective randomized studies using larger patient cohorts
are necessary to validate our findings.
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Supplementary
Table S1 Comparisons of perioperative outcomes between sleeve lobectomy and pneumonectomy after neoadjuvant treatment
Variables
Age (years), mean ± SD

Sleeve lobectomy (N=41)

Pneumonectomy (N=14)

P value

61.1±7.1

59.9±6.9

0.592

Gender, n (%)

0.601

Male

36 (87.8)

13 (92.9)

Female

5 (12.2)

1 (7.1)

Before neoadjuvant treatment

4.5±2.0

4.8±1.7

0.708

Before surgery

3.3±1.8

3.4±1.4

0.951

Radiologic tumor size (cm), mean ± SD

Clinical TNM stage

0.453

I

3 (7.3)

0 (0)

II

3 (7.3)

2 (14.3)

III

35 (85.4)

12 (85.7)

Neoadjuvant agents

0.646

ICI plus chemotherapy

14 (34.1)

3 (21.4)

EGFR-TKI

6 (14.6)

2 (14.3)

Chemotherapy alone

21 (51.2)

9 (64.3)

Surgical approach

0.066

VATS

29 (70.7)

5 (35.7)

Thoracotomy

9 (22.0)

7 (50.0)

VATS convert to thoracotomy

3 (7.3)

2 (14.3)

18.3±7.1

17.6±6.0

0.778

Examined N1 nodes

8.5±4.6

7.2±4.5

0.392

Examined N2 nodes

9.8±5.4

10.4±4.7

0.698

Surgical time (minutes), median (IQR)

212 (160–240)

141 (120–195)

0.079

Estimated blood loss (mL), median (IQR)

100 (50–200)

100 (50–300)

0.845

Required for postoperative transfusion, n (%)

5 (12.2)

5 (35.7)

0.049

Postoperative stay (days), median (IQR)

6 (4–7)

8 (7–12)

0.009

Perioperative mortality, n (%)

2 (4.9)

1 (7.1)

0.747

11 (26.8)

5 (35.7)

0.527

Bronchopleural fistula

2 (4.9)

0 (0)

0.400

Hemothorax

1 (2.4)

0 (0)

0.555

Chylothorax

1 (2.4)

1 (7.1)

0.417

Prolonged air leak

2 (4.9)

0 (0)

0.400

Pneumonia

5 (12.2)

4 (28.6)

0.153

Number of total examined LNs, mean ± SD

Postoperative complications, n (%)
Any complications

SD, standard deviation; TNM, tumor, node, metastasis; ICI, immune checkpoint inhibitor; EGFR-TKI, epidermal growth factor receptor
tyrosine kinase inhibitors; VATS, video-assisted thoracoscopic surgery; LN, lymph node; IQR, interquartile range.
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